1Gewirtz AM, Luger SM, Sokol D,etal.Treating human myelogenous leukemia with c-myb antisense oligodeoxynucleotides: Twoyears clinical experience[J].J Invest Med,1996；44:227a
2Fabritiis P, Amadori S, Petti MC, et al. In vitro purging with BCR-ABL antisenseoligodeoxynucleotides does not prevent haematologic reconstitation after antologous bonemarrow transplantation[J]. Leukemia,1995;9:662
4McGahon A,Bissonnette R,Schmitt M, et al. BCR-ABL maintains resistance of chronicmyelogenous leukemia cells to apoptotic cell death[J]. Blood, 1994;83:1179
5Calabretta B,Sims RB,Valiteri M,et al. Normal and leukemic hematopoietic cellsmanifest differential sensitivity to inhibitory effects to C-MYB antisenseoligodeoxynucleotides: An in vitro study relevant to bone marrow purging[J]. PN ASUSA, 1991;88:2351
6Skorski T, Nieborowska-Skorska M, Wlodarski P, et al. Antisenseoligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blastcrisis in SCID mice[J]. Blood, 1996;88:1005
7Maekawa T, Kimura S, Hirakawa K, et al. Sequence specificity on the growthsuppression cells by bcr-abl antisense oligodeoxynucleoside phosphorothioates[J]. IntJ Cancer, 1995;62:63
8Vaerman JL, Moureau P, Deldime F, et al. Antisense oligodeoxyrib-onucleotidessuppress hematologic cell growth through stepsise release of deoxyribonuclestides[J].Blood, 1997;90:3311
(收稿：1999-12-13)
